Blood Components

0
Blood Components is an Android app from NHS Blood and Transplant Patient Blood Management in the Medical category, currently rated — across few ratings. Initial signal reads as mixed reviews: supporters praise core features while critics cite stability and value gaps.
Quality Score is 0: Niche (micro-niche or pre-traction stage). For a Medical app, that means micro-niche or pre-traction stage. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
📊 Performance Tracking LIVE
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Medical complexity ×1.55 | +$27K |
| 🌐 Cross-platform reach (iOS + Android) | +$43K |
| ⚙ 9.6y maintenance × ~1-person team | +$57K |
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
| 📺 Ad-supported base | 15× MRR |
| 📅 9.6y proven track record | +20% |
| 🏷 Medical category multiple | +12% |
Heuristic guess from app bundle size, category, store description signals, and release-date stack era. Bumetric does not disassemble binaries — for binary-level certainty you would need an SDK intelligence tool or the manifest itself. Reasoning chain on the right. Full ruleset on /methodology.
| 🏷 Category context | Medical |
| 📦 Compact Android bundle | → Native Kotlin |
How we forecast this revenue
LOW CONFIDENCEBU Investment Matrix
Pre-traction · 35/100INDIE TIERlimited signal- 💰 Revenue: Marginal — $200 - $1250/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: None★ across 0 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: Insufficient signal to assess trajectory.
- ⚠️ Risk: Low — no material risk signals detected.
💰 Forecast Revenue / mo
MODEL📈 Reviews Growth
LIVE⭐ Rating Trend
LIVEProfile & Insights
Identification
- App name
- Blood Components
- Developer
- NHS Blood and Transplant Patient Blood Management
- Bundle ID
- uk.nhsbt.nhsbloodcomponents
- App Store URL
- Open in App Store
- Category
- Medical
- Content rating
- Not found
- Languages
- Not found
Company
- Website
- www.bloodcomponents.org.uk
- Tagline
- Not found
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Reported revenue signal / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- Model estimate / mo
- $500/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Funding
Press & Links
Contacts & Socials
📝 About this app
The App has been updated and is based on the National Blood Transfusion Committee (NBTC) Indication Codes for Transfusion (2020), the British Society of Haematology (BSH) Guideline on transfusion for foetuses, neonates and older children (2016) and The National Institute for Health and Care Excellence (NICE) Blood transfusion [NG24] guidelines . The App should be used in conjunction with the full guidelines.
Track this app’s revenue
FREE📝 Description
95
More by NHS Blood and Transplant Patient Blood Management
View all →Why low confidence: only 0 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
Blood Components is a very early-stage Android app in the medical space with weak public traction — only 0 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.



